Latest / Markets & Money News Today | 2 Min News | THE DAILY NOW!
Genmab Stock Jumps 9% After Trial Success | Markets & Money News
Genmab's stock surged 9% after announcing positive outcomes from a Phase 3 trial of rinatabart sesutecan (Rina-S) for platinum-resistant ovarian cancer. The RAINFOL-02 study reported significant improvements in progression-free and overall survival, with Rina-S reducing the risk of disease progression or death by 71% and the risk of death by 57%. The drug maintained a stable safety profile, and Genmab plans to present the full data and engage with regulatory authorities for approval. Exciting
www.TheDailyNewsNow.com
This is an automated, high-level news summary based on public reporting and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.